Correction to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.

Simple item page
cam.issuedOnline2018-07-30
dc.contributor.authorRitchie, Craig W
dc.contributor.authorRuss, Tom C
dc.contributor.authorBanerjee, Sube
dc.contributor.authorBarber, Bob
dc.contributor.authorBoaden, Andrew
dc.contributor.authorFox, Nick C
dc.contributor.authorHolmes, Clive
dc.contributor.authorIsaacs, Jeremy D
dc.contributor.authorLeroi, Ira
dc.contributor.authorLovestone, Simon
dc.contributor.authorNorton, Matt
dc.contributor.authorO'Brien, John
dc.contributor.authorPearson, Jim
dc.contributor.authorPerry, Richard
dc.contributor.authorPickett, James
dc.contributor.authorWaldman, Adam D
dc.contributor.authorWong, Wai Lup
dc.contributor.authorRossor, Martin N
dc.contributor.authorBurns, Alistair
dc.contributor.orcidO'Brien, John [0000-0002-0837-5080]
dc.date.accessioned2018-07-31T06:05:31Z
dc.date.available2018-07-31T06:05:31Z
dc.date.issued2018-07-30
dc.date.updated2018-07-31T06:05:28Z
dc.description.abstractSince the publication of this article [1], it has come to the attention of the authors that information for one of the authors was not included in the competing interests section. Craig Richie has declared potential competing interests with the following companies; Janssen, Eisai, Pfizer, Eli Lilly, Roche Diagnostics, Boeringher Ingleheim, Novartis, AC Immune, Ixico, Aridhia, Amgen, Berry Consultants, Lundbeck, Sanofi, Quintiles (IQVIA) and Takeda. The full competing interests section for this article can be found below.
dc.identifier.citationAlzheimer's Research & Therapy. 2018 Jul 30;10(1):73
dc.identifier.doi10.17863/CAM.25887
dc.identifier.eissn1758-9193
dc.identifier.issn1758-9193
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/278555
dc.language.rfc3066en
dc.publisherSpringer Science and Business Media LLC
dc.publisher.urlhttp://dx.doi.org/10.1186/s13195-018-0372-0
dc.rightsAll Rights Reserved
dc.rights.holderThe Author(s).
dc.rights.urihttps://www.rioxx.net/licenses/all-rights-reserved/
dc.subject1109 Neurosciences
dc.titleCorrection to: The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease.
dc.typeArticle
dcterms.dateAccepted2018-04-06
prism.publicationNameAlzheimers Res Ther
pubs.funder-project-idMedical Research Council (MR/L023784/2)
pubs.funder-project-idMedical Research Council (MR/L023784/1)
rioxxterms.versionofrecord10.1186/s13195-018-0372-0
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
13195_2018_Article_372.pdf
Size:
464.93 KB
Format:
Adobe Portable Document Format
Licence
https://www.rioxx.net/licenses/all-rights-reserved/
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
12.8 KB
Format:
Item-specific license agreed upon to submission
Download
Collections
BioMed Central Publications